John Cox's appointment, with his vast biotech industry and rare disease commercialization experience, is viewed positively for Dyne Therapeutics. His leadership is anticipated to enhance the company's clinical programs and pipeline, and build more capabilities as Dyne continues to create stakeholder value.
Recent insider share sale at current price raises slight concern. Lack of insider buying and low level of insider ownership over the past year do not inspire excitement about the stock.
The lack of recent insider transactions and low insider ownership at Dyne Therapeutics doesn't inspire confidence. Insider sales at prices above current levels could suggest contentment with lower valuations, potentially a weak sign for future stock performance.
$戴纳基(DYN.US)$Press Release: Dyne Therapeutics Announces Closing of Public Offering of Common Stock and Full Exercise by Underwriters of Option to Purchase Additional Shares Dow Jones· just
SlowndEasyTrades楼主103896218:
This back in previous recent deep high re-test range we might see rebound over 30 sooner currently this has negetive 35 million free cash little bit risky
FiReBiTriXiE :
She’s going up a tad Imma wait till close I have her on Robinhood and can’t do shit till 7am which is retarded but I love the platform non the less lol
戴纳基股票讨论区
$戴纳基(DYN.US)$ 4% Closing of public offering
$杰龙(GERN.US)$ 4% Participate @ B. Riley Sec. Conf. '24
$ZEALAND PHARMA AS SPON ADR EACH REP 1 ORD SHS(ZEAL.US)$ 2% Capital increase
$标记临床研究(XOMA.US)$ 1% Arimoclomol NDA filing accepted
$Cellectar BioSciences(CLRB.US)$ 1% Topline results @ conf. call
$CytomX(CTMX.US)$ 0% Present @ B. Riley Sec. Conf. '24
Dow Jones· just
$戴纳基(DYN.US)$ alert 13+ dips load
$Volcon(VLCN.US)$ alert 0.09 dips load
$BIO-key International(BKYI.US)$ alert 2.5-2.8 dips load
$Lytus Technologies Holdings(LYT.US)$ alert 0.108 dips
4 MINUTES AGO, 4:25 PM EST
VIA GLOBENEWSWIRE
暂无评论